Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy

Dagmar F. Hernandez-Suarez, Hector Núñez-Medina, Stuart A. Scott, Angel Lopez-Candales, Jose M. Wiley, Mario J. Garcia, Kyle Melin, Karid Nieves-Borrero, Christina Rodriguez-Ruiz, Lorraine Marshall, Jorge Duconge

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Antiplatelet therapy with clopidogrel is recommended to reduce cardiovascular events in patients with peripheral artery disease (PAD); however, clopidogrel efficacy has not been adequately studied in this patient population. Therefore, we aimed to determine the effects of cilostazol therapy on platelet reactivity among PAD patients on clopidogrel. We performed a cross-sectional pilot study of 46 Puerto Rican patients diagnosed with PAD. The cohort was divided based on use of clopidogrel and cilostazol (n=24) or clopidogrel alone (n=22). Platelet function was measured ex vivo using the VerifyNow P2Y12 assay. Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Midi Kit, which was subjected to candidate variant genotyping (CYP2C19, ABCB1, PON1 and P2RY12) using TaqMan quantitative polymerase chain reaction assays. All analyses were performed using SAS version 9.4 (SAS Institute). Among all enrolled patients, 18 (39%) had high on-treatment platelet reactivity (HTPR). The mean platelet reactivity was 207±53 (range, 78-325) with higher P2Y12 reaction units in the non-cilostazol group, 224±45 vs. 191±55 on the cilostazol group (p=0.03). No significant differences were observed in the clinical or genetic variables between the two groups. A multiple regression analysis determined that history of diabetes mellitus (p=0.03), use of cilostazol (p=0.03) and hematocrit (p=0.02) were independent predictors of platelet reactivity. In Puerto Rican PAD patients on clopidogrel therapy, history of diabetes mellitus, use of cilostazol and hematocrit are independent predictors of platelet reactivity. Adjunctive cilostazol therapy may enhance clopidogrel efficacy among PAD patients with HTPR.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalDrug Metabolism and Personalized Therapy
Volume33
Issue number1
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

clopidogrel
Peripheral Arterial Disease
Blood Platelets
Hematocrit
Hispanic Americans
Therapeutics
Diabetes Mellitus
DNA
cilostazol

Keywords

  • cilostazol
  • clopidogrel
  • peripheral artery disease
  • platelet reactivity

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. / Hernandez-Suarez, Dagmar F.; Núñez-Medina, Hector; Scott, Stuart A.; Lopez-Candales, Angel; Wiley, Jose M.; Garcia, Mario J.; Melin, Kyle; Nieves-Borrero, Karid; Rodriguez-Ruiz, Christina; Marshall, Lorraine; Duconge, Jorge.

In: Drug Metabolism and Personalized Therapy, Vol. 33, No. 1, 01.03.2018, p. 49-55.

Research output: Contribution to journalArticle

Hernandez-Suarez, DF, Núñez-Medina, H, Scott, SA, Lopez-Candales, A, Wiley, JM, Garcia, MJ, Melin, K, Nieves-Borrero, K, Rodriguez-Ruiz, C, Marshall, L & Duconge, J 2018, 'Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy', Drug Metabolism and Personalized Therapy, vol. 33, no. 1, pp. 49-55. https://doi.org/10.1515/dmpt-2017-0032
Hernandez-Suarez, Dagmar F. ; Núñez-Medina, Hector ; Scott, Stuart A. ; Lopez-Candales, Angel ; Wiley, Jose M. ; Garcia, Mario J. ; Melin, Kyle ; Nieves-Borrero, Karid ; Rodriguez-Ruiz, Christina ; Marshall, Lorraine ; Duconge, Jorge. / Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. In: Drug Metabolism and Personalized Therapy. 2018 ; Vol. 33, No. 1. pp. 49-55.
@article{8a004f6fcd7a4c27814e894a444d8a8f,
title = "Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy",
abstract = "Antiplatelet therapy with clopidogrel is recommended to reduce cardiovascular events in patients with peripheral artery disease (PAD); however, clopidogrel efficacy has not been adequately studied in this patient population. Therefore, we aimed to determine the effects of cilostazol therapy on platelet reactivity among PAD patients on clopidogrel. We performed a cross-sectional pilot study of 46 Puerto Rican patients diagnosed with PAD. The cohort was divided based on use of clopidogrel and cilostazol (n=24) or clopidogrel alone (n=22). Platelet function was measured ex vivo using the VerifyNow P2Y12 assay. Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Midi Kit, which was subjected to candidate variant genotyping (CYP2C19, ABCB1, PON1 and P2RY12) using TaqMan quantitative polymerase chain reaction assays. All analyses were performed using SAS version 9.4 (SAS Institute). Among all enrolled patients, 18 (39{\%}) had high on-treatment platelet reactivity (HTPR). The mean platelet reactivity was 207±53 (range, 78-325) with higher P2Y12 reaction units in the non-cilostazol group, 224±45 vs. 191±55 on the cilostazol group (p=0.03). No significant differences were observed in the clinical or genetic variables between the two groups. A multiple regression analysis determined that history of diabetes mellitus (p=0.03), use of cilostazol (p=0.03) and hematocrit (p=0.02) were independent predictors of platelet reactivity. In Puerto Rican PAD patients on clopidogrel therapy, history of diabetes mellitus, use of cilostazol and hematocrit are independent predictors of platelet reactivity. Adjunctive cilostazol therapy may enhance clopidogrel efficacy among PAD patients with HTPR.",
keywords = "cilostazol, clopidogrel, peripheral artery disease, platelet reactivity",
author = "Hernandez-Suarez, {Dagmar F.} and Hector N{\'u}{\~n}ez-Medina and Scott, {Stuart A.} and Angel Lopez-Candales and Wiley, {Jose M.} and Garcia, {Mario J.} and Kyle Melin and Karid Nieves-Borrero and Christina Rodriguez-Ruiz and Lorraine Marshall and Jorge Duconge",
year = "2018",
month = "3",
day = "1",
doi = "10.1515/dmpt-2017-0032",
language = "English (US)",
volume = "33",
pages = "49--55",
journal = "Drug Metabolism and Personalized Therapy",
issn = "2363-8907",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1",

}

TY - JOUR

T1 - Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy

AU - Hernandez-Suarez, Dagmar F.

AU - Núñez-Medina, Hector

AU - Scott, Stuart A.

AU - Lopez-Candales, Angel

AU - Wiley, Jose M.

AU - Garcia, Mario J.

AU - Melin, Kyle

AU - Nieves-Borrero, Karid

AU - Rodriguez-Ruiz, Christina

AU - Marshall, Lorraine

AU - Duconge, Jorge

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Antiplatelet therapy with clopidogrel is recommended to reduce cardiovascular events in patients with peripheral artery disease (PAD); however, clopidogrel efficacy has not been adequately studied in this patient population. Therefore, we aimed to determine the effects of cilostazol therapy on platelet reactivity among PAD patients on clopidogrel. We performed a cross-sectional pilot study of 46 Puerto Rican patients diagnosed with PAD. The cohort was divided based on use of clopidogrel and cilostazol (n=24) or clopidogrel alone (n=22). Platelet function was measured ex vivo using the VerifyNow P2Y12 assay. Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Midi Kit, which was subjected to candidate variant genotyping (CYP2C19, ABCB1, PON1 and P2RY12) using TaqMan quantitative polymerase chain reaction assays. All analyses were performed using SAS version 9.4 (SAS Institute). Among all enrolled patients, 18 (39%) had high on-treatment platelet reactivity (HTPR). The mean platelet reactivity was 207±53 (range, 78-325) with higher P2Y12 reaction units in the non-cilostazol group, 224±45 vs. 191±55 on the cilostazol group (p=0.03). No significant differences were observed in the clinical or genetic variables between the two groups. A multiple regression analysis determined that history of diabetes mellitus (p=0.03), use of cilostazol (p=0.03) and hematocrit (p=0.02) were independent predictors of platelet reactivity. In Puerto Rican PAD patients on clopidogrel therapy, history of diabetes mellitus, use of cilostazol and hematocrit are independent predictors of platelet reactivity. Adjunctive cilostazol therapy may enhance clopidogrel efficacy among PAD patients with HTPR.

AB - Antiplatelet therapy with clopidogrel is recommended to reduce cardiovascular events in patients with peripheral artery disease (PAD); however, clopidogrel efficacy has not been adequately studied in this patient population. Therefore, we aimed to determine the effects of cilostazol therapy on platelet reactivity among PAD patients on clopidogrel. We performed a cross-sectional pilot study of 46 Puerto Rican patients diagnosed with PAD. The cohort was divided based on use of clopidogrel and cilostazol (n=24) or clopidogrel alone (n=22). Platelet function was measured ex vivo using the VerifyNow P2Y12 assay. Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Midi Kit, which was subjected to candidate variant genotyping (CYP2C19, ABCB1, PON1 and P2RY12) using TaqMan quantitative polymerase chain reaction assays. All analyses were performed using SAS version 9.4 (SAS Institute). Among all enrolled patients, 18 (39%) had high on-treatment platelet reactivity (HTPR). The mean platelet reactivity was 207±53 (range, 78-325) with higher P2Y12 reaction units in the non-cilostazol group, 224±45 vs. 191±55 on the cilostazol group (p=0.03). No significant differences were observed in the clinical or genetic variables between the two groups. A multiple regression analysis determined that history of diabetes mellitus (p=0.03), use of cilostazol (p=0.03) and hematocrit (p=0.02) were independent predictors of platelet reactivity. In Puerto Rican PAD patients on clopidogrel therapy, history of diabetes mellitus, use of cilostazol and hematocrit are independent predictors of platelet reactivity. Adjunctive cilostazol therapy may enhance clopidogrel efficacy among PAD patients with HTPR.

KW - cilostazol

KW - clopidogrel

KW - peripheral artery disease

KW - platelet reactivity

UR - http://www.scopus.com/inward/record.url?scp=85042041900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042041900&partnerID=8YFLogxK

U2 - 10.1515/dmpt-2017-0032

DO - 10.1515/dmpt-2017-0032

M3 - Article

C2 - 29408797

AN - SCOPUS:85042041900

VL - 33

SP - 49

EP - 55

JO - Drug Metabolism and Personalized Therapy

JF - Drug Metabolism and Personalized Therapy

SN - 2363-8907

IS - 1

ER -